Related Experiment Videos
Prognostic markers for systemic sclerosis
1Assistance publique-Hôpitaux de Paris, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France. olivier.meyer@bch.aphp.fr
Joint Bone Spine
|June 27, 2006
Summary
Systemic sclerosis prognosis is linked to skin lesion extent and specific autoantibodies. Certain autoantibodies and biomarkers predict organ involvement and mortality risk in scleroderma patients.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Prognosis in systemic sclerosis (SSc) is significantly influenced by the extent of skin involvement, which often correlates with the severity of cardiovascular, pulmonary, and renal complications.
- Specific autoantibodies play a crucial role in SSc, with associations to distinct organ manifestations and overall survival.
Purpose of the Study:
- To elucidate the prognostic value of autoantibody profiles and identify biomarkers for predicting organ involvement and mortality in systemic sclerosis.
- To analyze the relationship between autoantibody patterns, extent of skin disease, and patient survival rates.
Main Methods:
- Retrospective analysis of a large cohort (1432 patients) from the Pittsburgh Scleroderma Databank.
- Correlation of autoantibody status (anticentromere, anti-topoisomerase I, anti-RNA polymerase III, etc.) with clinical data, including skin extent and survival.
- Evaluation of serum biomarkers (KL-6, SP-A, SP-D, PIIINP, homocysteine, CD40L, NP-ProBNP, VCAM1, etc.) for predicting specific organ involvement.
Main Results:
- Mortality risk increases 2.5- to 3-fold with erythrocyte sedimentation rate >15-25 mm/h or hemoglobin <12.5-11 g/dl.
- Distinct autoantibodies are linked to specific complications: anticentromere antibodies with pulmonary hypertension, anti-topoisomerase I (Scl 70) with interstitial lung disease, and anti-RNA polymerase III with renovascular hypertension.
- Ten-year survival rates varied significantly based on autoantibody profile and skin disease type (limited vs. diffuse cutaneous SSc). For example, limited cutaneous SSc patients with anti-U1-RNP had 88% 10-year survival, while those with anti-Th/To had 65%.
Conclusions:
- Autoantibody patterns are critical determinants of prognosis and mortality risk in systemic sclerosis.
- Several serum biomarkers show potential for predicting specific organ involvement, aiding in risk stratification and management of SSc.
- Further research is needed to validate the predictive performance of emerging biomarkers for organ involvement in SSc.